tetano
Editor, Senior Moderator
Sci Rep. 2016 Nov 29;6:37999. doi: 10.1038/srep37999.
[h=1]Rapid control of pandemic H1N1 influenza by targeting NKT-cells.[/h] Artiaga BL[SUP]1[/SUP], Yang G[SUP]1[/SUP], Hutchinson TE[SUP]2[/SUP], Loeb JC[SUP]3[/SUP], Richt JA[SUP]4[/SUP], Lednicky JA[SUP]3,[/SUP][SUP]5[/SUP], Salek-Ardakani S[SUP]2[/SUP], Driver JP[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Swine influenza A viruses (IAV) are a major cause of respiratory disease in pigs and humans. Currently approved anti-influenza therapies directly target the virus, but these approaches are losing effectiveness as new viral strains quickly develop drug resistance. To over come this challenge, there is an urgent need for more effective antiviral drugs. Here we tested the anti-influenza efficacy of the invariant natural killer T (NKT) cell superagonist, α-galactosylceramide (α-GalCer), which stimulates a wide array of anti-viral immune responses. We show that intranasal but not systemic administration of α-GalCer to piglets infected with pandemic A/California/04/2009 (CA04) H1N1 IAV ameliorated disease symptoms and resulted in the restoration of weight gain to the level of uninfected pigs. Correspondingly, viral titers in the upper-and lower-respiratory tract were reduced only in piglets that had received intranasal α-GalCer. Most significantly, lung inflammation as a consequence of virus persistence was largely prevented when NKT-cells were targeted via the respiratory route. Thus, targeting mucosal NKT-cells may provide a novel and potent platform for improving the course of disease in swine infected with seasonal and pandemic influenza viruses, and leads to the suggestion that this may also be true in humans and therefore deserves further study.
PMID: 27897246 DOI: 10.1038/srep37999
[PubMed - in process]
[h=1]Rapid control of pandemic H1N1 influenza by targeting NKT-cells.[/h] Artiaga BL[SUP]1[/SUP], Yang G[SUP]1[/SUP], Hutchinson TE[SUP]2[/SUP], Loeb JC[SUP]3[/SUP], Richt JA[SUP]4[/SUP], Lednicky JA[SUP]3,[/SUP][SUP]5[/SUP], Salek-Ardakani S[SUP]2[/SUP], Driver JP[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Swine influenza A viruses (IAV) are a major cause of respiratory disease in pigs and humans. Currently approved anti-influenza therapies directly target the virus, but these approaches are losing effectiveness as new viral strains quickly develop drug resistance. To over come this challenge, there is an urgent need for more effective antiviral drugs. Here we tested the anti-influenza efficacy of the invariant natural killer T (NKT) cell superagonist, α-galactosylceramide (α-GalCer), which stimulates a wide array of anti-viral immune responses. We show that intranasal but not systemic administration of α-GalCer to piglets infected with pandemic A/California/04/2009 (CA04) H1N1 IAV ameliorated disease symptoms and resulted in the restoration of weight gain to the level of uninfected pigs. Correspondingly, viral titers in the upper-and lower-respiratory tract were reduced only in piglets that had received intranasal α-GalCer. Most significantly, lung inflammation as a consequence of virus persistence was largely prevented when NKT-cells were targeted via the respiratory route. Thus, targeting mucosal NKT-cells may provide a novel and potent platform for improving the course of disease in swine infected with seasonal and pandemic influenza viruses, and leads to the suggestion that this may also be true in humans and therefore deserves further study.
PMID: 27897246 DOI: 10.1038/srep37999
[PubMed - in process]